ECSP15008695A - Combinaciones farmacéuticas que comprenden un inhibidor de b-raf, un inhibidor de egfr y opcionalmente un inhibidor de pi3k-alfa - Google Patents
Combinaciones farmacéuticas que comprenden un inhibidor de b-raf, un inhibidor de egfr y opcionalmente un inhibidor de pi3k-alfaInfo
- Publication number
- ECSP15008695A ECSP15008695A ECIEPI20158695A ECPI201508695A ECSP15008695A EC SP15008695 A ECSP15008695 A EC SP15008695A EC IEPI20158695 A ECIEPI20158695 A EC IEPI20158695A EC PI201508695 A ECPI201508695 A EC PI201508695A EC SP15008695 A ECSP15008695 A EC SP15008695A
- Authority
- EC
- Ecuador
- Prior art keywords
- inhibitor
- optionally
- pi3k
- egfr
- raf
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención se refiere a una combinación terapéutica, la cual comprende: (a) un inhibidor de B-Raf, (b) un inhibidor del receptor del factor de crecimiento epidérmico (EGFR) y, opcionalmente, (c) un inhibidor de PI3K, útil para su 5 administración separada, simultánea o en secuencia en un sujeto que lo necesite, para el tratamiento o la prevención de una enfermedad proliferativa. La presente invención se refiere en especial a una combinación terapéutica, la cual comprende: (a) un inhibidor de B-Raf de la fórmula: 10 o una sal farmacéuticamente aceptable del mismo (posteriormente referido en la presente como el Compuesto A), (b) un inhibidor del receptor del factor de crecimiento epidérmico (EGFR) y, opcionalmente, 15 (c) un inhibidor de PI3K.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261680473P | 2012-08-07 | 2012-08-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP15008695A true ECSP15008695A (es) | 2019-03-29 |
Family
ID=48980368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECIEPI20158695A ECSP15008695A (es) | 2012-08-07 | 2015-03-06 | Combinaciones farmacéuticas que comprenden un inhibidor de b-raf, un inhibidor de egfr y opcionalmente un inhibidor de pi3k-alfa |
Country Status (39)
| Country | Link |
|---|---|
| US (1) | US9474754B2 (es) |
| EP (2) | EP2882440B1 (es) |
| JP (3) | JP6342396B2 (es) |
| KR (1) | KR102112885B1 (es) |
| CN (1) | CN104519887B (es) |
| AR (1) | AR092045A1 (es) |
| AU (1) | AU2013299841B8 (es) |
| CA (1) | CA2879548C (es) |
| CL (1) | CL2015000294A1 (es) |
| CO (1) | CO7200273A2 (es) |
| CY (1) | CY1122143T1 (es) |
| DK (1) | DK2882440T3 (es) |
| EA (1) | EA028420B1 (es) |
| EC (1) | ECSP15008695A (es) |
| ES (1) | ES2717911T3 (es) |
| GT (1) | GT201500025A (es) |
| HK (1) | HK1211831A1 (es) |
| HR (1) | HRP20190537T1 (es) |
| HU (1) | HUE042877T2 (es) |
| IL (1) | IL236934B (es) |
| IN (1) | IN2015DN00450A (es) |
| JO (1) | JOP20130236B1 (es) |
| LT (1) | LT2882440T (es) |
| MA (1) | MA37829A1 (es) |
| MX (1) | MX359403B (es) |
| MY (1) | MY176031A (es) |
| NZ (1) | NZ703940A (es) |
| PE (2) | PE20150673A1 (es) |
| PH (1) | PH12015500246B1 (es) |
| PL (1) | PL2882440T3 (es) |
| PT (1) | PT2882440T (es) |
| RS (1) | RS58734B1 (es) |
| SG (1) | SG11201500321YA (es) |
| SI (1) | SI2882440T1 (es) |
| TN (1) | TN2015000027A1 (es) |
| TR (1) | TR201904980T4 (es) |
| TW (1) | TWI607754B (es) |
| UA (1) | UA115786C2 (es) |
| WO (1) | WO2014025688A1 (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY176031A (en) * | 2012-08-07 | 2020-07-22 | Array Biopharma Inc | Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor |
| WO2014147573A2 (en) | 2013-03-21 | 2014-09-25 | Novartis Ag | Combination therapy |
| WO2015145388A2 (en) * | 2014-03-27 | 2015-10-01 | Novartis Ag | Methods of treating colorectal cancers harboring upstream wnt pathway mutations |
| US11124836B2 (en) * | 2014-06-16 | 2021-09-21 | Worldwide Innovative Network | Method for selecting personalized tri-therapy for cancer treatment |
| WO2016193955A1 (en) * | 2015-06-04 | 2016-12-08 | Giorgio Stassi | Combinations of kinase inhibitors for treating colorectal cancer |
| WO2017037578A2 (en) * | 2015-08-28 | 2017-03-09 | Novartis Ag | Combination therapy |
| US10328065B2 (en) | 2015-08-28 | 2019-06-25 | Novartis Ag | Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the B-RAF inhibitor dabrafenib; the use of such combination in the treatment or prevention of cancer |
| WO2017066664A1 (en) * | 2015-10-16 | 2017-04-20 | Millennium Pharmaceuticals, Inc. | Combination therapy including a raf inhibitor for the treatment of colorectal cancer |
| BR112018074941A2 (pt) * | 2016-06-03 | 2019-03-12 | Caponigro Giordano | combinações farmacêuticas |
| AU2017329090B9 (en) | 2016-09-19 | 2019-09-05 | Novartis Ag | Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor |
| TWI798218B (zh) | 2017-05-02 | 2023-04-11 | 瑞士商諾華公司 | 組合療法 |
| EP3661516A1 (en) * | 2017-08-03 | 2020-06-10 | Novartis AG | Therapeutic combination of a third-generation egfr tyrosine kinase inhibitor and a raf inhibitor |
| SI3860998T1 (sl) | 2018-10-05 | 2024-06-28 | Annapurna Bio Inc. | Spojine in sestavki za zdravljenje stanj, povezanih z aktivnostjo apj-receptorja |
| TWI849043B (zh) * | 2019-01-25 | 2024-07-21 | 英屬開曼群島商百濟神州有限公司 | B-raf激酶二聚體抑制劑之穩定固體分散體、製備方法及其用途 |
| WO2020164997A1 (en) * | 2019-02-12 | 2020-08-20 | Bayer Aktiengesellschaft | Combination of pi3k-inhibitors |
| MX2021013817A (es) | 2019-05-13 | 2021-12-14 | Novartis Ag | Nuevas formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinop iridin-4-il)-4-metilfenil)-2-(trifluorometil)isonicotinamida como inhibidores de raf para el tratamiento del cancer. |
| JPWO2023145530A1 (es) * | 2022-01-27 | 2023-08-03 | ||
| WO2023230554A1 (en) | 2022-05-25 | 2023-11-30 | Pfizer Inc. | Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer |
| TW202421133A (zh) * | 2022-09-26 | 2024-06-01 | 美商馬布可爾公司 | 用於治療癌症的ｂ－ｒａｆ抑制劑和抗ｅｇｆｒ抗體之組合 |
| WO2025003956A1 (en) | 2023-06-30 | 2025-01-02 | Pfizer Inc. | High drug loading formulations of encorafenib |
| WO2025262686A1 (en) * | 2024-06-20 | 2025-12-26 | Ilan Paz | Devices, systems and methods for optimized, personalized administration of oral dosage forms |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US8513266B2 (en) | 2007-04-10 | 2013-08-20 | Exelixis, Inc. | Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K alpha |
| UA104147C2 (uk) * | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
| CA2771369A1 (en) * | 2009-08-24 | 2011-03-10 | Genentech, Inc. | Determining sensitivity of cells to b-raf inhibitor treatment by detecting kras mutation and rtk expression levels |
| AR077975A1 (es) | 2009-08-28 | 2011-10-05 | Irm Llc | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina |
| EA020965B1 (ru) * | 2009-10-12 | 2015-03-31 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | Способ и фармацевтическая комбинация для лечения рака |
| US20120045433A1 (en) | 2010-08-17 | 2012-02-23 | Kapil Dhingra | Combination therapy |
| CA2815492C (en) * | 2010-11-08 | 2019-04-09 | Novartis Ag | Use of 2-carboxamide cycloamino urea derivatives in the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members |
| CA2855245A1 (en) | 2011-11-10 | 2013-05-16 | Memorial Sloan-Kettering Cancer Center | Treatment of ovarian cancer with 2-amino-4h-naphtho[1,2-b]pyran-3-carbonitriles |
| AU2012335663B2 (en) * | 2011-11-11 | 2015-12-24 | Array Biopharma Inc. | Method of treating a proliferative disease |
| MY176031A (en) * | 2012-08-07 | 2020-07-22 | Array Biopharma Inc | Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor |
-
2013
- 2013-08-05 MY MYPI2015000102A patent/MY176031A/en unknown
- 2013-08-05 PT PT13748243T patent/PT2882440T/pt unknown
- 2013-08-05 EA EA201590332A patent/EA028420B1/ru not_active IP Right Cessation
- 2013-08-05 JP JP2015526606A patent/JP6342396B2/ja active Active
- 2013-08-05 TR TR2019/04980T patent/TR201904980T4/tr unknown
- 2013-08-05 RS RS20190351A patent/RS58734B1/sr unknown
- 2013-08-05 HK HK15110834.2A patent/HK1211831A1/xx unknown
- 2013-08-05 MX MX2015001732A patent/MX359403B/es active IP Right Grant
- 2013-08-05 EP EP13748243.6A patent/EP2882440B1/en active Active
- 2013-08-05 DK DK13748243.6T patent/DK2882440T3/da active
- 2013-08-05 LT LTEP13748243.6T patent/LT2882440T/lt unknown
- 2013-08-05 WO PCT/US2013/053619 patent/WO2014025688A1/en not_active Ceased
- 2013-08-05 KR KR1020157002982A patent/KR102112885B1/ko active Active
- 2013-08-05 US US14/419,256 patent/US9474754B2/en active Active
- 2013-08-05 SI SI201331387T patent/SI2882440T1/sl unknown
- 2013-08-05 SG SG11201500321YA patent/SG11201500321YA/en unknown
- 2013-08-05 IN IN450DEN2015 patent/IN2015DN00450A/en unknown
- 2013-08-05 CN CN201380042229.5A patent/CN104519887B/zh active Active
- 2013-08-05 ES ES13748243T patent/ES2717911T3/es active Active
- 2013-08-05 HU HUE13748243A patent/HUE042877T2/hu unknown
- 2013-08-05 PL PL13748243T patent/PL2882440T3/pl unknown
- 2013-08-05 AU AU2013299841A patent/AU2013299841B8/en active Active
- 2013-08-05 PE PE2015000130A patent/PE20150673A1/es not_active Application Discontinuation
- 2013-08-05 EP EP19159506.5A patent/EP3574904A1/en active Pending
- 2013-08-05 PE PE2019001539A patent/PE20191655A1/es unknown
- 2013-08-05 UA UAA201500424A patent/UA115786C2/uk unknown
- 2013-08-05 HR HRP20190537TT patent/HRP20190537T1/hr unknown
- 2013-08-05 NZ NZ703940A patent/NZ703940A/en unknown
- 2013-08-05 AR ARP130102776A patent/AR092045A1/es not_active Application Discontinuation
- 2013-08-05 CA CA2879548A patent/CA2879548C/en active Active
- 2013-08-06 JO JOP/2013/0236A patent/JOP20130236B1/ar active
- 2013-08-06 TW TW102128165A patent/TWI607754B/zh active
-
2015
- 2015-01-19 TN TNP2015000027A patent/TN2015000027A1/fr unknown
- 2015-01-26 IL IL236934A patent/IL236934B/en active IP Right Grant
- 2015-02-04 PH PH12015500246A patent/PH12015500246B1/en unknown
- 2015-02-04 MA MA37829A patent/MA37829A1/fr unknown
- 2015-02-06 GT GT201500025A patent/GT201500025A/es unknown
- 2015-02-06 CL CL2015000294A patent/CL2015000294A1/es unknown
- 2015-02-06 CO CO15024921A patent/CO7200273A2/es unknown
- 2015-03-06 EC ECIEPI20158695A patent/ECSP15008695A/es unknown
-
2018
- 2018-02-09 JP JP2018022248A patent/JP6595024B2/ja active Active
-
2019
- 2019-04-30 CY CY20191100461T patent/CY1122143T1/el unknown
- 2019-09-25 JP JP2019174353A patent/JP6974669B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP15008695A (es) | Combinaciones farmacéuticas que comprenden un inhibidor de b-raf, un inhibidor de egfr y opcionalmente un inhibidor de pi3k-alfa | |
| UA117451C2 (uk) | Терапевтично активні сполуки і способи їх застосування | |
| AR091876A1 (es) | Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas | |
| CY1119490T1 (el) | Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων | |
| NI201400083A (es) | Compuesto de imidazopirrolidinona | |
| CR20120419A (es) | Formulación de anticuerpos y regimenes terapéuticos | |
| PE20121617A1 (es) | Derivados de oxazina como inhibidores de bace | |
| MX2018007815A (es) | Tetrahidropiranil amino-pirrolopirimidinona y metodos de uso de la misma. | |
| MX391858B (es) | Compuestos terapeuticamente activos y sus metodos de uso | |
| MX2013013437A (es) | 4-amino-5-fluoro-3- [6- (4-metil-piperazin-1-il) -1h-bencimidazol-2-il] -1h-quinolin-2-ona parea usarse en el tratamiento de un carcinoma adenoide quistico. | |
| MX2014002171A (es) | Tratamientos de combinacion para hepatitis c. | |
| MX382516B (es) | Composiciones y metodos para absorcion transmucosa. | |
| GT201500053A (es) | Composicion farmaceutica recubierta que contiene regorafenib | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| CU20140037A7 (es) | Derivados de estra- 1,3,5(10), 16- tetraen- 3- carboximida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos | |
| MX369518B (es) | Combinacion de inhibidor de p13k e inhibidor de c-met. | |
| PH12016502353A1 (en) | Pharmaceutical composition | |
| MX2012013879A (es) | Derivados de hidroxipiridona, composiciones farmceuticas de los mismos y su uso terapeutico para tratar enfermedades proliferativas. | |
| CO6561789A2 (es) | Método de tratamiento | |
| TW201613577A (en) | Pharmaceutical combinations | |
| ECSP13012847A (es) | Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparación. | |
| UY33529A (es) | Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias? | |
| BR112015012497A2 (pt) | combinações farmacêuticas | |
| MX362905B (es) | Tratamiento de combinacion. | |
| BR112014030288A8 (pt) | composição farmacêutica, uso da mesma, e, uso de metanossulfonilacetonitrila |